FC PROTEIN AND GLYCOENGINEERED ANTIBODIES MARKET ANALYSIS

Fc Protein and Glycoengineered Antibodies Market, by Drug (Approved Drugs (Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi)) and Pipeline drugs (Ublituximab and Others)), by Application (Oncology, Autoimmune Disease, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Oct 2024
Code : CMI2626
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Fc Protein and Glycoengineered Antibodies Market Key Players

Some of the major players operating in the global Fc protein and glycoengineered antibodies market include Kyowa Hakko Kirin Co. Ltd., Merck KGaA, Boehringer Ingelheim International GmbH, AstraZeneca Plc, Amgen Inc., Genentech Inc., Five Prime Therapeutics Inc., Celldex Therapeutics, Clovis Oncology, and TG Therapeutics, Inc.